Jesus G. Berdeja, MD, discusses the dosing of the investigational CAR T-cell product JNJ-4528 in patients with relapsed/refractory multiple myeloma.
Jesus G. Berdeja, MD
Advertisement
Articles by Jesus G. Berdeja, MD
Jesus G. Berdeja, MD, discusses updated safety results from the ongoing phase 1b/2 CARTITUDE-1 trial (NCT03548207) with the CAR T-cell therapy JNJ-4528 in multiple myeloma.
Advertisement
Latest Updated Articles
Dr. Berdeja on Updated CARTITUDE-1 Results With JNJ-4258 in Multiple MyelomaPublished: June 15th 2020 | Updated:
Dr. Berdeja on Dosing JNJ-4528 in Relapsed/Refractory Multiple MyelomaPublished: July 8th 2020 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Assessing FDA-Approved CAR-T in Patients With Multiple Myeloma and Renal Failure
2
FDA Approves Waskyra as First Gene Therapy for Wiskott-Aldrich Syndrome
3
Rabi Hanna, MD, on Evaluating Gene Editing Therapy Reni-Cel for Severe Sickle Cell Disease
4
Hematology-Oncology Immunotherapy Highlights at ASH 2025
5
